Immunological profile of a Plasmodium vivax AMA-1 N-terminus peptide-carbon nanotube conjugate in an infected Plasmodium berghei mouse model
We have covalently conjugated an N-terminus Plasmodium vivax apical membrane antigen-1 (AMA-1) peptide to functionalized carbon nanotubes (f-CNT). Immunological characterization of this molecular conjugate revealed that the immunogen-AMA-1 peptide was appropriately presented after being conjugated t...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2008
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/23447
- Acceso en línea:
- https://doi.org/10.1016/j.vaccine.2008.08.014
https://repository.urosario.edu.co/handle/10336/23447
- Palabra clave:
- Apical membrane antigen 1
Carbon nanotube
Drug carrier
Polyclonal antibody
Amino terminal sequence
Animal experiment
Animal model
Article
Bagg albino mouse
Conjugation
Controlled study
Drug delivery system
Drug structure
Female
Immune system
Immunogenicity
Malaria
Mouse
Nonhuman
Parasitemia
Plasmodium berghei
Plasmodium vivax
Priority journal
Alleles
Amino acid sequence
Animals
Cytokines
Drug delivery systems
Enzyme-linked immunosorbent assay
Female
Fluorescent antibody technique
Hla-dr antigens
Malaria
Malaria vaccines
Membrane proteins
Mice
Molecular sequence data
Nanotubes
Plasmodium berghei
Plasmodium vivax
Protozoan proteins
Apical membrane antigen 1 (ama-1)
Functionalized carbon nanotubes (f-cnt)
Synthetic vaccine delivery system
protozoan
mhc class ii
subunit
western
inbred balb c
electron
Antigens
Blotting
Genes
Mice
Microscopy
Vaccines
- Rights
- License
- Abierto (Texto Completo)
Summary: | We have covalently conjugated an N-terminus Plasmodium vivax apical membrane antigen-1 (AMA-1) peptide to functionalized carbon nanotubes (f-CNT). Immunological characterization of this molecular conjugate revealed that the immunogen-AMA-1 peptide was appropriately presented after being conjugated to CNTs as well as being recognized by BALB/c polyclonal antibodies. Subsequent experiments lead us to assess the AMA-1 peptide alone, as well as the CNT-peptide conjugate regarding rodent malarial infection. Remarkably, the peptide effectively controlled and delayed Plasmodium berghei-challenged animals' parasitaemia. The peptide-CNT conjugate displayed similar immunological properties to the peptide alone by protecting or delaying malarial infection. The peptide presentation by f-CNT to the immune system thus constitutes a promising approach for synthetic malarial vaccine formulation since the immunogen peptide conformation is well preserved. © 2008 Elsevier Ltd. All rights reserved. |
---|